Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04913337 · ClinicalTrials.gov registry record · Phase 1

Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies

A Phase 1 study of Breast Cancer and Non-Small Cell Lung Cancer, sponsored by NGM Biopharmaceuticals.

Active
Registry status
Phase 1
Development phase
179
Enrollment target
20
Study locations

NCT04913337 is a Phase 1 study of Breast Cancer and Non-Small Cell Lung Cancer that is active but no longer recruiting, run by NGM Biopharmaceuticals. The registered enrollment target is 179 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (94% lower). The trial reports 20 study locations across 13 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04913337, a Phase 1 study of Breast Cancer and Non-Small Cell Lung Cancer, is active but no longer recruiting, sponsored by NGM Biopharmaceuticals.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
179 participants
Enrollment target
20
Study locations

Study Summary

Study of NGM707 as Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies

Conditions Studied

Breast Cancer Non-Small Cell Lung Cancer Melanoma Glioblastoma Gastric Cancer Renal Cell Carcinoma Pancreatic Ductal Adenocarcinoma Cholangiocarcinoma Mesothelioma Squamous Cell Carcinoma of Head and Neck

Interventions

  • DRUG NGM707
  • DRUG NGM707 plus pembrolizumab (KEYTRUDA®)

Study Locations (20)

Texas

  • NGM Clinical Study Site - Dallas
  • NGM Clinical Study Site - Dallas
  • NGM Clinical Study Site - Houston
  • NGM Clinical Study Site - San Antonio
  • NGM Clinical Study Site - San Antonio

California

  • NGM Clinical Study Site - Los Angeles
  • NGM Clinical Study Site - Newport Beach
  • NGM Clinical Study Site - Santa Monica
  • NGM Clinical Study Site - Santa Rosa

Colorado

  • NGM Clinical Study Site - Lone Tree

District of Columbia

  • NGM Clinical Study Site - Washington D.C.

Florida

  • NGM Clinical Study Site - Sarasota

Maryland

  • NGM Clinical Study Site - Baltimore

Massachusetts

  • NGM Clinical Study Site - Boston

Michigan

  • NGM Clinical Study Site - Grand Rapids

Trial Details

FieldValue
Enrollment Target 179 participants
Start Date 2021-06-09
Est. Completion 2025-07
Phase Phase 1

Sponsor

NGM Biopharmaceuticals

18 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04913337

The ClinicalTrials.gov registry entry for NCT04913337 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 179 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (94% lower). The listed sponsor is NGM Biopharmaceuticals, which has 18 total studies on file at ClinicalTrials.gov.

The record links to 10 conditions, with Breast Cancer appearing as the primary indexed condition, and to 2 interventions - of which NGM707 is the first listed.

NCT04913337 reports 20 study locations spanning 13 distinct geographic areas - top geographies include Texas, California, Colorado.

Frequently Asked Questions

What is clinical trial NCT04913337 about?

NCT04913337 is a clinical study titled "Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies". Study of NGM707 as Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies

What is the current status of trial NCT04913337?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 179 participants. The study started on 2021-06-09. Estimated completion is 2025-07.

What conditions does trial NCT04913337 study?

This clinical trial studies the following conditions: Breast Cancer, Non-Small Cell Lung Cancer, Melanoma, Glioblastoma, Gastric Cancer.

What interventions are being tested in trial NCT04913337?

The interventions under investigation include: NGM707 (DRUG), NGM707 plus pembrolizumab (KEYTRUDA®) (DRUG).

Who is sponsoring clinical trial NCT04913337?

This trial is sponsored by NGM Biopharmaceuticals, which has 18 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04913337 being conducted?

This trial has 20 study locations across California, Colorado, District of Columbia, Florida, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Breast Cancer

All registered trials for this condition

Non-Small Cell Lung Cancer

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.